Biomarkers for the development of cancer vaccines - Current status

被引:14
作者
Copier, John
Whelan, Mike
Dalgleish, Angus
机构
[1] St Georges Univ London, Dept Oncol, Div Cellular & Mol Med, London SW17 0RE, England
[2] St Georges Univ London, Onyvax Ltd, London, England
关键词
D O I
10.1007/BF03256210
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Significant improvements in our knowledge of tumor immunology have resulted in more sophisticated vaccine approaches for the treatment of cancer. However, research into biomarkers that correlate with the clinical outcome of immunotherapy has lagged behind vaccine development. To this extent, very few immunological or other markers exist that can be used in clinical trials for immunotherapy. In this review, we discuss the current status of biomarker development specifically for the monitoring and development of cancer vaccines. This includes immunological biomarkers (measurement of T-cell and cytokine responses), autoimmunity as a correlate for treatment outcome, and the possible development of multiple biomarkers using high-throughput proteomics technologies. The generation of such biomarkers will allow us to make clinical decisions about patient treatment at an earlier stage and should aid in shortening the development time for vaccines.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 56 条
[1]   Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].
Attia, P ;
Phan, GQ ;
Maker, AV ;
Robinson, MR ;
Quezado, MM ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Kammula, US ;
Royal, RE ;
Restifo, NP ;
Haworth, LR ;
Levy, C ;
Mavroukakis, SA ;
Nichol, G ;
Yellin, MJ ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053
[2]   Dendritic cells as therapeutic vaccines against cancer [J].
Banchereau, J ;
Palucka, AK .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306
[3]   Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer [J].
Belluco, C ;
Nitti, D ;
Frantz, M ;
Toppan, P ;
Basso, D ;
Plebani, M ;
Lise, M ;
Jessup, JM .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :133-138
[4]  
Bendardaf R, 2004, ANTICANCER RES, V24, P2519
[5]   New methods for assessing T-Cell responses [J].
Bercovici, N ;
Duffour, MT ;
Agrawal, S ;
Salcedo, M ;
Abastado, JP .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, 7 (06) :859-864
[6]  
Bicciato S, 2004, CURR OPIN MOL THER, V6, P616
[7]   Immunization with mutant p53- and K-ras-derived peptides in cancer patients:: Immune response and clinical outcome [J].
Carbone, DP ;
Ciernik, IF ;
Kelley, MJ ;
Smith, MC ;
Nadaf, S ;
Kavanaugh, D ;
Maher, VE ;
Stipanov, M ;
Contois, D ;
Johnson, BE ;
Pendleton, CD ;
Seifert, B ;
Carter, C ;
Read, EJ ;
Greenblatt, J ;
Top, LE ;
Kelsey, MI ;
Minna, JD ;
Berzofsky, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5099-5107
[8]   Protein chip array profiling analysis of sera from neuroblastoma patients [J].
Combaret, V ;
Bergeron, C ;
Bréjon, S ;
Iacono, I ;
Perol, D ;
Négrier, S ;
Puisieux, A .
CANCER LETTERS, 2005, 228 (1-2) :91-96
[9]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[10]   Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome [J].
de Vries, IJM ;
Bernsen, MR ;
Lesterhuis, WJ ;
Scharenborg, NM ;
Strijk, SP ;
Gerritsen, MJP ;
Ruiter, DJ ;
Figdor, CG ;
Punt, CJA ;
Adema, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5779-5787